83647-97-6

Basic information

• Product Name: Spirapril
• Synonyms: SPIRAPRIL;SPIRAPRIL FOR SYSTEM SUITABILITY EPY;SPIRAPRIL FOR SYSTEM SUITABILITY EPY(CRM STANDARD);(8S-(7(R*(R*)),8R*))-7-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid;Sandopfil;Sch-33844;Spiraprilic acid;1,4-Dithia-7-azaspiro(4,4)nonane-8-carboxylic acid, 7-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-, (8S-(7(R*(R*)),8R*))-
• CAS NO: 83647-97-6
• Molecular Formula: C₂₂H₃₀N₂O₅S₂
• Molecular Weight: 466.61
• Mol File: 83647-97-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 697.8 °C at 760 mmHg
• Flash Point: 375.8 °C
• Appearance: /
• Density: 1.32 g/cm³
• Vapor Pressure: 1.93E-20mmHg at 25°C
• Refractive Index: 1.621
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Spirapril(CAS DataBase Reference)
• NIST Chemistry Reference: Spirapril(83647-97-6)
• EPA Substance Registry System: Spirapril(83647-97-6)

Safety Data

• Hazardous Substances Data: 83647-97-6(Hazardous Substances Data)

Usage

General Description

Spirapril is a pharmaceutical drug that belongs to the class of medications known as angiotensin-converting enzyme (ACE) inhibitors. It is used to treat high blood pressure and heart failure. Spirapril works by blocking the action of ACE, an enzyme in the body that causes the blood vessels to constrict, ultimately lowering blood pressure and improving the function of the heart. It is often prescribed as part of a comprehensive treatment plan for individuals with hypertension or heart failure. Spirapril is available in oral tablet form and is typically taken once or twice daily, as directed by a healthcare provider. Common side effects may include dizziness, cough, and lightheadedness.

InChI:InChI=1/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1

Upstream product

• 83552-44-7 1,4-dithia-7-azaspiro<4.4>nonane-8(S)-carboxylic acid 
• 113949-44-3 (S)-1,4-Dithia-7-aza-spiro[4.4]nonane-7,8-dicarboxylic acid 7-tert-butyl ester 8-(2-trimethylsilanyl-ethyl) ester 
• 83623-66-9 (S)-7-(tert-butoxycarbonyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid 
• 64187-47-9 1-benzyloxycarbonyl-4-keto-L-proline 
• 83507-90-8 N-<(phenylmethoxy)carbonyl>-1,4-dithia-7-azaspiro<4.4>nonane-8(S)-carboxylic acid ethyl ester 
• 83507-89-5 N-<(phenylmethoxy)carbonyl>-4-oxo-(S)-proline ethyl ester 
• 82717-96-2 [1(S)-(ethoxycarbonyl)-3-phenylpropyl]-(S)-alanine 
• 89371-34-6 N-succinimidyl (2S)-2-{N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]amino}propionate 
• 503322-63-2 C₂₅H₃₈N₂O₅S₂Si 

Downstream Products

• 94841-17-5 spirapril hydrochloride 
• 83602-05-5 Spiraprilat 

Relevant articles and documents

Angiotensin Converting Enzyme Inhibitors: Spirapril and Related Compounds

The synthesis of spirapril (5), spiraprilat (25), their RSS stereoisomers, and their glycyl (18b) and lysyl (36, 37) analogues is described.These compounds were evaluated in vivo for inhibition of angiotensin converting enzyme (ACE), and selected compounds were evaluated for in vitro ACE inhibition (spirapril ID50 16 μg/kg; spiraprilat IC50 0.8 nM, ID50 8 μg/kg).In anesthetized rats, iv, esters 5 and 36 are more potent than enalapril, and diacids 25 and 37 are more potent than enalaprilat in vitro.In the conscious rats, orally, 5 and enalapril (2) showed potent and sustained activity at doses of 0.03-1 and 0.1-1 mg/kg, respectively.From this work, spirapril was selected for clinical evaluation as an antihypertensive agent.